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Abstract
SARS-CoV-2 (COVID-19) is associated with increased thrombosis. Here, we demonstrate patterns of pulmonary vascular disease
in COVID-19 including classical acute pulmonary embolism and subsegmental perfusion defects in the absence of acute pulmonary
embolism suggestive of microvascular thrombosis.
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Introduction
Severe acute respiratory syndrome (SARS) caused by the
coronavirus SARS-CoV-2 (COVID-19) has a high mortality
due primarily to respiratory failure. Recent studies
have highlighted increased thrombosis in COVID-19.1
Extensive microvascular thrombosis has been noted at
post-mortem and high rates of pulmonary embolism (PE)
diagnosed using computed tomography pulmonary angiog-
raphy (CTPA),2 alongside lung parenchymal changes.3
There has been increasing interest in the patterns of pulmo-
nary vascular involvement due to COVID-19 and concern
that perfusion abnormalities may represent in-situ throm-
bosis that may not be appreciated on standard CTPA. The
British Thoracic Imaging Society Guidelines recommend
unenhanced pulmonary angiography and CTPA. This pro-
tocol facilitates lung subtraction iodine mapping (CT-
LSIM) for lung perfusion, a clinically sensitive tool in PE.
We report the first CT-LSIM images in COVID-19.
Materials and methods
At our institution, 10 patients (mean age (SD) 70 (16), 40%
female) with COVID-19, confirmed on reverse transcription
polymerase chain reaction (RT-PCR), underwent CTPA
and CT-LSIM for suspected acute PE based on clinical
assessment and elevated d-dimer levels (Table 1). Analysis
of CT images was approved by our institution review board.
Results
Three patients had confirmed PE on CTPA and CT-LSIM
(one case is shown in Fig. 1 (1a, 1b, 1c)). Another patient
had perfusion defects on CT-LSIM without visible PE
where CT-LISM showed subsegmental perfusion defects
without visible PE (Fig. 1 (2a, 2b, 2c)). Six patients did
not have perfusion defects on CT-LSIM.
Discussion
Distinct from classical thromboembolic PE, a high propor-
tion of in situ pulmonary arterial thrombosis exists in
COVID-19, and the pathophysiology is not fully under-
stood.4 Here, we demonstrate patterns of pulmonary vascu-
lar disease in COVID-19 including (i) classical acute PE
with central clot associated with lung infarction and (ii)
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Table 1. Patients’ characteristics.







Age, years 70 (16) 73 (17) 68 (18)
Female, n 4 3 1
Race or ethnic group, n
White 8 4 4
Black 1 1 0
Other ethnicity 1 1 0
Comorbidities, n
Obesity 2 1 1
Smoker 3 2 1
Immunosuppression 2 1 1
Malignancy 1 0 1
Chronic obstructive pulmonary disease 1 1 0
Asthma 2 1 1
Ischaemic heart disease 1 0 1
Hypertension 5 2 3
Diabetes mellitus 2 1 1
Chronic kidney disease 1 0 1
Symptoms and signs around time for CTPA, n
Tachycardia 4 2 2
Chest pain 2 1 1
Hypoxia 8 4 4
Intubation 2 1 1
Length of hospital stay, days 23 (13) 17 (16) 27 (15)
Critical care admission, n 5 2 3
Peak d-dimer 30 days prior to CTPA, ng/mla 1637 (1075–18,902) 1160 (870–15,240) 8130 (2339–23,317)
Peak c-reactive protein 7 days prior to CTPA, mg/L 192 (127) 204 (84) 181 (170)
Peak Ferritin 30 days prior to CTPA, lg/La 1036 (347–1928) 1089 (218–1360) 982 (342–1801)


































subsegmental perfusion defects in the absence of acute PE
which is perhaps suggestive of microvascular thrombosis.
CT-LSIM is potentially widely available for the assess-
ment of lung perfusion in COVID-19. Further studies to
understand the pathophysiology of pulmonary thrombotic
disease in COVID-19 are required.
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Figure 1. Patterns of parenchymal, vascular, and perfusion abnormalities in COVID-19. Patient 1: (a) Peripheral wedge-shaped abnormality in
the right lower lobe associated with a segmental filling defect (blue arrows) on CTPA (b) corresponding to a perfusion defect (green arrows) on
CT-LSIM (c). Patient 2: (a) Absence of lung parenchymal involvement and normal pulmonary vasculature on CTPA (b) with a perfusion defect in
the right upper lobe on CT-LSIM (c, green arrows).
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